StreetAlpha.app
Home › Stocks › SLN

Silence Therapeutics plc (SLN)

Healthcare
$19.81
▲ +0.00%
LAST CLOSE · NOV 20

Silence Therapeutics develops siRNA medicines that switch off disease-linked genes, with candidates for blood, heart and obesity conditions. It last closed at $19.81 on Nov 20, up 0.00% on the day. The next earnings report for SLN is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, SLN reported EPS of -$0.08 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 8 reports the stock moved an average of 6.6% the session after earnings.

AI Auto Pilots
Is SLN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SLN.

Key Stats

Last 12 months
Results
Revenue
$456K
−98.2% vs a year ago
Net income
−$51.4M
−11276.5% margin
EPS (diluted)
−$0.35
Free cash flow
−$44.1M
−9681.6% margin
Valuation
Market cap
$3.7B
186.6M shares
P/E
–
No P/E while losing money
Price to sales
8106.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$247.7M
At Sep 30
Shareholder equity
$215.0M
Shares outstanding
186.6M
At Sep 30
ExchangeNasdaq
Financials history
FY2022: $21.7M$21.7MFY2022FY2023: $31.6M$31.6MFY2023FY2024: $43.3M$43.3MFY2024FY2025: $559K$559KFY2025

From SLN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$0.08
Quarter ended Sep 2026
Year ago EPS
-$0.15
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.09Dec '24Mar 2025: -$0.20Mar '25Jun 2025: -$0.19Jun '25Sep 2025: -$0.15Sep '25Dec 2025: -$0.09Dec '25Mar 2026: -$0.11Mar '26Jun 2026: -$0.09Jun '26Sep 2026: -$0.08Sep '26Latest -$0.08
Revenue by quarter
Dec 2024: $25.3MDec '24Mar 2025: $142,000Mar '25Jun 2025: $224,000Jun '25Sep 2025: $159,000Sep '25Dec 2025: $34,000Dec '25Mar 2026: $422,000Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How SLN moved after its last 8 reports
Average move the session after a report ±6.6%
Nov 12, 2026Time not announced+0.1%
Aug 10, 2026Time not announced+29.1%
May 7, 2026Time not announced−5.6%
Mar 5, 2026Time not announced−4.8%
Nov 6, 2025Time not announced+3.4%
Aug 7, 2025Time not announced+1.1%
May 8, 2025Time not announced−3.8%
Feb 27, 2025After the close−4.7%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SLNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SLN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SLN

Technical Analysis

SLN · as of the Nov 20 close · updated each morning
Uptrend, overbought

The stock is 0% above its 20 day and 23% above its 50 day average. It is 49% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 78), overbought. The nearest support is the Pivot S1 at $19.80, and the nearest resistance the Pivot R1 at $19.83.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityLow, 1.4%/day
Key levels
$19.8652 week high+0.3%
$19.86Swing high (Nov 13)+0.3%
$19.83Pivot R1+0.1%
$19.81Pivot+0.0%
$19.81Last close
$19.80Pivot S1−0.1%
$19.7820 day average−0.2%
$19.70Swing low (Nov 9)−0.6%
$15.2850 day average−22.9%
$13.78100 day average−30.4%
$10.16200 day average−48.7%
$4.1952 week low−78.8%
Indicators
RSI (14)77.56Overbought above 70Overbought
MACD1.20Below its signal lineBearish
Stochastic73.1Middle of its rangeNeutral
ADX (14)58.1Strong uptrend
Williams %R-29.0Oversold below −80, overbought above −20Neutral
CCI (20)101.2Oversold below −100, overbought above 100Overbought
Rate of change+0.4%Change over 10 sessionsBullish
ATR (14)$0.28Typical daily range, 1.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SLN

What happened before

See how SLN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SLN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SLN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SLNHow many large options trades hit SLN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SLN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 28 selling
  • ▲Held by funds +13.2 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 5 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9272+27.8%
In funds' top 1041+300.0%
Held by funds25.9%12.6%+13.2 pts
New / increased34 / 3820 / 22+71.4%
Reduced / sold out15 / 1318 / 4+27.3%
Put/call ratio0.070.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SLN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SLN is in one of them and how their past SLN trades turned out.

SLN in the AI portfolios
Loading…

SLN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SLN in an article yet. Here's the latest on the wider market.

SLN in the news

About Silence Therapeutics

Silence Therapeutics is a biotechnology company based in London that develops small interfering RNA, or siRNA, medicines. These molecules work by switching off specific genes linked to disease in the liver, which lowers the proteins those genes produce. Its candidates target rare blood disorders, heart and cholesterol conditions, and obesity. The company is also seeking outside partners to help take some of these treatments further.

Headquarters
London